newsbytesapp.com2d
This drug shows promise in extending bladder cancer patients' lives
This is the first instance of an immunotherapy drug significantly improving overall survival in patients with this type of ...
AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage Muscle-Invasive Bladder Cancer Trial
AstraZeneca Plc (AZN.L, AZN) announced that the NIAGARA Phase III trial showed its IMFINZI (durvalumab) in combination with ...
ESMO 2024: Imfinzi to be practice changing in perioperative bladder cancer setting
The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.
ENDPOINTS NEWS2d
As­traZeneca un­veils what it calls ‘prac­tice-chang­ing’ Imfinzi da­ta in blad­der can­cer
In a result that's likely to change how some bladder cancer patients get care, AstraZeneca said that its drug Imfinzi boosted patient survival alongside chemotherapy and surgery. Two years after ...
The Pharma Letter2d
ESMO 2024: Imfinzi NIAGARA Phase III trial success in bladder cancer
Positive results from the NIAGARA Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab) ...
Cure Today2d
Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC
Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...
AstraZeneca and MSD hail progress in tackling hard-to-treat cancers
Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...
FiercePharma3d
ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
Cure Today1d
Adaptive NSCLC Study Fails to Produce Improved Results, Clinical Benefits in Some
Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations ...